Duloxetine HCL DR Capsules
Pre-Solicitation Posted
This opportunity was awarded. See the award notice from , or the latest solicitation from .
- Solicitation number
- SPE2D2-25-R-0010
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Not on record
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical is preparing to issue a national requirements contract for Duloxetine HCL DR Capsules across multiple dosage strengths and bottle quantities. The procurement will be an unrestricted and fully competitive acquisition using FAR part 12 for commercial items, with a firm-fixed price requirements-type contract structure. The contract will consist of a one-year base period with four additional one-year option periods, establishing a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through DLA and VA prime vendor programs. Interested parties can submit proposals and should contact Christopher Newman with any questions or comments. The solicitation is projected to be released in April 2025 and will be posted on the DLA Bid Board System (DIBBS) and Sam.Gov.
The pre-solicitation notice indicates no specific set-aside designations for this contract opportunity. The procurement will cover Duloxetine HCL DR Capsules in multiple strengths: 20MG in 60 count bottles, 30MG in 30 and 90 count bottles, 40MG in 30 count bottles, and 60MG in 30 and 1000 count bottles. While specific award values were not disclosed, the contract is designed to meet national requirements across multiple federal agencies. The comprehensive nature of the contract suggests a potentially significant procurement volume, with annual usage estimates to be detailed in the Schedule of Supplies section of the final solicitation. DLA reserves the right to issue the solicitation before or after the projected April 2025 date, providing flexibility in the procurement timeline.
Notice text
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR Capsules. Procurement details follow.
Duloxetine HCL DR 20MG Capsules in 60 count bottles, 30MG Capsules in 30 and 90 count bottles, 40MG Capsules in 30 count bottles, and 60MG Capsules in 30 and 1000 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.
A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov/. Interested parties should contact Christopher Newman (445-737-7371) (christopher.newman@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is April of 2025. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Duloxetine HCL DR Capsules | Award Notice | |
| Duloxetine HCL DR Capsules | Solicitation | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Methylphenidate ER | Medical Supply Chain | No set-aside | |
| Epinephrine Injector | Medical Supply Chain | No set-aside | |
| 6505--Imatinib Tablets | National Acquisition Center | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity